Click Here! Click Here!
 
Click Here!
Search archive       
VOL. 10 No. 1, FEBRUARY 2011

First-line use of second-generation tyrosine kinase inhibitors in cml-cp


Clinical impact of funding decisions in multiple myeloma


Literature-based followup recommendations.
Part 3: Common hematologic malignancies

Reports from ASH

Multiple myeloma: optimizing patient outcome with maintenance therapies

lymphoma: improving time to initiation of new therapy

cancer-associated thrombosis: identification of patients at low risk for recurrent thrombosis

hematopoietic stem cell transplantation: impact of in vivo t-cell depletion

Reports from ESMO and SABCS

neuroendocrine tumours: radiant-2 and -3 treatment advances

pancreatic cancer: folfirinox vs gemcitabine as first-line treatment

breast CANCER: options for high-risk triple-negative disease

breast CANCER: improved prognosis for TNBC patients


MEDICAL MEETINGS ROSTER

DRUG & THERAPEUTIC UPDATES

 

 
 

We welcome your letters and suggestions for future articles.

Please address correspondence
to Susan Usher, Editor,
at
usher@parkpub.com

Click Here! Click Here!
© Parkhurst Publishing Privacy Statement
Legal Terms of Use